Frontiers in Medical Science Research, 2023, 5(1); doi: 10.25236/FMSR.2023.050111.
Tian Wu, Rong Hu
Department of Ultrasound in Obstetrics and Gynecology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Key Laboratory of Ultrasound Medicine No.137, Liyu Shan South Road, Urumgi, Xinjiang, 830054, China
Epithelial ovarian cancer (EOC) is one of the major malignant tumors that seriously threaten women's health. Due to the lack of effective screening tools and vague symptoms, more than 70% of ovarian cancer patients are not diagnosed until the advanced stage, so it is difficult to treat them. Ultrasound targeted microbubble destruction (UTMD) technology shows great advantages in the delivery of clinical therapeutic materials, and can significantly improve the therapeutic effect. Therefore, the application of UTMD in the treatment of ovarian cancer has attracted the attention of excellent scholars at home and abroad. This article reviews targeted ultrasound contrast agents and their application strategies in the treatment of ovarian cancer.
ovarian cancer, contrast agents, targeted contrast agent, microbubble, ultrasound targeted microbubble
Tian Wu, Rong Hu. Application of Targeted Ultrasound Contrast Agent in Ovarian Cancer. Frontiers in Medical Science Research (2023) Vol. 5, Issue 1: 60-64. https://doi.org/10.25236/FMSR.2023.050111.
[1] Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review [J]. Semin Oncol Nurs, 2019, 35(2): 151-156.
[2] Shampo M A, Kyle R A. Karl Theodore Dussik--pioneer in ultrasound [J]. Mayo Clin Proc, 1995, 70(12): 1136.
[3] Schutt E G, Klein D H, Mattrey R M, et al. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: the key role of perfluorochemicals [J]. Angew Chem Int Ed Engl, 2003, 42(28): 3218-3235.
[4] Pellow C, Abenojar E C, Exner A A, et al. Concurrent visual and acoustic tracking of passive and active delivery of nanobubbles to tumors [J]. Theranostics, 2020, 10(25): 11690-11706.
[5] Walsby A E. Gas vesicles [J]. Microbiol Rev, 1994, 58(1): 94-144.
[6] Le Floc'h J, Zlitni A, Bilton H A, et al. In vivo Biodistribution of Radiolabeled Acoustic Protein Nanostructures [J]. Mol Imaging Biol, 2018, 20(2): 230-239.
[7] Chen W, Liu X, Li Y, et al. Preparation and In Vitro Evaluation of a Nano Ultrasound Contrast Agent Targeting Pancreatic Cancer [J]. J Nanosci Nanotechnol, 2021, 21(3): 1413-1418.
[8] Kimura M, Miyahara K, Yamasaki M, et al. Comparison of vascular endothelial growth factor/vascular endothelial growth factor receptor 2 expression and its relationship to tumor cell proliferation in canine epithelial and mesenchymal tumors [J]. J Vet Med Sci, 2022, 84(1): 133-141.
[9] Jia M, Li Q, Guo J, et al. Deletion of BACH1 Attenuates Atherosclerosis by Reducing Endothelial Inflammation [J]. Circ Res, 2022, 130(7): 1038-1055.
[10] Perera R H, Abenojar E, Nittayacharn P, et al. Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stability in vivo and in vitro [J]. Nanotheranostics, 2022, 6(3): 270-285.
[11] Zhu Q, Xu X, Chen B, et al. Ultrasound-targeted microbubbles destruction assists dual delivery of beta-amyloid antibody and neural stem cells to restore neural function in transgenic mice of Alzheimer's disease [J]. Med Phys, 2022, 49(3): 1357-1367.
[12] Penny S M. Ovarian Cancer: An Overview [J]. Radiol Technol, 2020, 91(6): 561-575.
[13] Yang C, Xia B R, Zhang Z C, et al. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant [J]. Front Immunol, 2020, 11: 577869.
[14] Mirza M R, Coleman R L, González-Martín A, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors [J]. Ann Oncol, 2020, 31(9): 1148-1159.
[15] Bound N T, Vandenberg C J, Kartikasari A E R, et al. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system [J]. Front Genet, 2022, 13: 886170.
[16] Lampert E J, Zimmer A, Padget M, et al. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study [J]. Clin Cancer Res, 2020, 26(16): 4268-4279.
[17] Kuroki L, Guntupalli S R. Treatment of epithelial ovarian cancer [J]. Bmj, 2020, 371: m3773.
[18] Gao Y, Hernandez C, Yuan H X, et al. Ultrasound molecular imaging of ovarian cancer with CA-125 targeted nanobubble contrast agents [J]. Nanomedicine, 2017, 13(7): 2159-2168.
[19] Hu R, Zeng Q, Su X, et al. The Correlation between Targeted Contrast-Enhanced Ultrasound Imaging and Tumor Neovascularization of Ovarian Cancer Xenografts in Nude Mice [J]. J Healthc Eng, 2021, 2021: 5553649.
[20] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[21] Wang Q, Wu C, Li X, et al. Cisplatin and paclitaxel co-delivery nanosystem for ovarian cancer chemotherapy [J]. Regen Biomater, 2021, 8(3): rbab015.
[22] DeVorkin L, Hattersley M, Kim P, et al. Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma [J]. Mol Cancer Res, 2017, 15(3): 250-258.
[23] Fan G, Qin J, Fu X, et al. Low-Intensity Focused Ultrasound Targeted Microbubble Destruction Enhanced Paclitaxel Sensitivity by Decreasing Autophagy in Paclitaxel-Resistant Ovarian Cancer [J]. Front Oncol, 2022, 12: 823956.
[24] Woźniak M, Pastuch-Gawołek G, Makuch S, et al. In Vitro and In Vivo Efficacy of a Novel Glucose-Methotrexate Conjugate in Targeted Cancer Treatment [J]. Int J Mol Sci, 2021, 22(4).
[25] Fathi M, Barar J, Erfan-Niya H, et al. Methotrexate-conjugated chitosan-grafted pH- and thermo-responsive magnetic nanoparticles for targeted therapy of ovarian cancer [J]. Int J Biol Macromol, 2020, 154: 1175-1184.
[26] Vergote I, González-Martín A, Ray-Coquard I, et al. European experts consensus: BRCA/ homologous recombination deficiency testing in first-line ovarian cancer [J]. Ann Oncol, 2022, 33(3): 276-287.
[27] Verma I M, Somia N. Gene therapy -- promises, problems and prospects [J]. Nature, 1997, 389(6648): 239-242.
[28] Oberle V, de Jong G, Drayer J I, et al. Efficient transfer of chromosome-based DNA constructs into mammalian cells [J]. Biochim Biophys Acta, 2004, 1676(3): 223-230.
[29] Li Y, Du M, Fang J, et al. UTMD promoted local delivery of miR-34a-mimic for ovarian cancer therapy [J]. Drug Deliv, 2021, 28(1): 1616-1625.
[30] Li H, Liu Y, Wang Y, et al. Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review) [J]. Oncol Rep, 2021, 46(4).
[31] Arecco L, Ruelle T, Martelli V, et al. How to Protect Ovarian Function before and during Chemotherapy? [J]. J Clin Med, 2021, 10(18).
[32] Chang S, Guo J, Sun J, et al. Targeted microbubbles for ultrasound mediated gene transfection and apoptosis induction in ovarian cancer cells [J]. Ultrason Sonochem, 2013, 20(1): 171-179.
[33] Li Y, Lu W, Yang J, et al. Survivin as a biological biomarker for diagnosis and therapy [J]. Expert Opin Biol Ther, 2021, 21(11): 1429-1441.
[34] Zhang Y, Chang S, Sun J, et al. Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780/DDP Cells [J]. Mol Pharm, 2015, 12(9): 3137-3145.
[35] Kim H K, Kim S A, Jung E K, et al. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer [J]. Oncol Rep, 2021, 45(4).
[36] Xu X, Yu S, Liu X, et al. Ultrasound-Targeted Microbubble Destruction-Mediated Inhibition of Livin Expression Accelerates Ovarian Cancer Cell Apoptosis [J]. Genet Res (Camb), 2021, 2021: 7624346.
[37] Davis A, Morris K V, Shevchenko G. Hypoxia-directed tumor targeting of CRISPR-Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles [J]. Mol Ther Methods Clin Dev, 2022, 25: 158-169.
[38] Zhou X L, Shi Y L, Li X. Inhibitory effects of the ultrasound-targeted microbubble destruction- mediated herpes simplex virus-thymidine kinase/ganciclovir system on ovarian cancer in mice [J]. Exp Ther Med, 2014, 8(4): 1159-1163.